Biologics

The FDA granted Carmell Therapeutics Fast Track designation on April 27 for its debut product, a bone healing accelerant, OA Online reports.

Stefanos Theoharis, PhD, was appointed chief business officer of Bone Therapeutics on March 26.

Zolgensma, Novartis' gene therapy drug for spinal muscular atrophy, recently demonstrated significant therapeutic benefits for patients in various extended clinical trials, reports Pharmaceutical Technology.

The Japanese Ministry of Health, Labour and Welfare recently approved Zolgensma, Novartis' gene therapy drug for the treatment of spinal muscular atrophy, for infants under the age of 2, according to Medical Dialogues.

Regenerative medicine therapies hold much potential in the orthopedic space, despite the lack of comprehensive knowledge around the therapies. Here, Anika Therapeutics interim CEO Cheryl Blanchard, PhD, explains how the company plans to approach the biologics market.

SpineOvations on Feb 24. finished enrollment for its DiscSeal clinical study in patients suffering from lumbar pain.

Roger Härtl, MD, has devoted much of his career to finding the best, least invasive treatment for back and neck pain. That mission has led him to research and innovate in the field of spinal biologics.

Konica Minolta Healthcare Americas partnered with RegenLab USA Feb. 19 to distribute its regenerative medicine portfolio for the orthopedic market in the U.S. and Canada.

Early-stage research published in npg Regenerative Medicine demonstrated that two medications on the market can enhance the body's ability to heal by releasing stem cells from bone marrow, reports Science Blog.

Neel Anand, MD, serves as professor of orthopedic surgery and director of spine trauma at the Cedars-Sinai Spine Center in Los Angeles.